A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy
K.-C. Chang(Chang Gung University), Tsung‐Hui Hu(National Sun Yat-sen University), Yi‐Hao Yen(Chang Gung University), Shih‐Chieh Lin(Baylor College of Medicine), Chia‐Hsiang Chen(Center for HIV and Hepatogastroenterology), Ming‐Chang Tsai(Chung Shan Medical University Hospital), Po‐Lin Tseng(Chang Gung University), J.-H. Wang(Chang Gung University), S.-N. Lu(Chang Gung University), Chien‐Hui Hung(Kaohsiung Chang Gung Memorial Hospital), C.-M. Lee(Chang Gung University), Miaofen Yen(Taipei Medical University)
Cited by 101
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Hepatogastroenterology
|Hepatogastroenterology|2012|536
Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients
|Gastroenterology|2007|232
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|Liver International|2016|221
Clinical characteristics and prognostic factors of splenic abscess: A review of 67 cases in a single medical center of Taiwan
|World Journal of Gastroenterology|2006|217